HCT CHART upward indication, page-621

“This is a product that already has a nice safety profile and has an application that has allowed it to move forward in the clinic. We believe this is a product we can rapidly advance in a realistic way,” Rohan said. “With adequate funding, we’re hoping to move the product into the clinic before the end of the year.”

1. They have not tested any active ingredient (the antiviral protein) on the surrogate COVID19 yet so no confirmation that it would kill the actual COVID19. Most likely it will but the fact they haven't even tested it yet makes it seem like it's quite far off from turning this idea into production. whilst HCT is already proven and has most likely started producing already our balm already (hence the patent pending).
2 They don't have adequate funding to even produce it yet as quoted in the article. HCT not only has everything up and running, but will be distributing it by the third quarter.
3. Even if they find some funding, they would only hope to "move the product into the CLINIC before the end of the year", by which then, Natshield nasal balm would be everywhere already.

HCT is way in front of the curve with this nasal balm. Exciting times ahead.